Pushing the limits: Defeating leukemia stem cells by depleting telomerase

Academic Article

Abstract

  • © 2014 Elsevier Inc. Leukemia stem cells (LSCs), featuring unlimited self-renewal capacity and chemoresistance, are critical cellular targets for new treatments to improve outcomes for acute myeloid leukemia (AML). In this issue of Cell Stem Cell, Bruedigam et al. (2014) demonstrate that inhibition of telomerase is damaging to LSCs and may represent a promising therapeutic approach in AML.
  • Digital Object Identifier (doi)

    Author List

  • Kuo YH; Bhatia R
  • Start Page

  • 673
  • End Page

  • 675
  • Volume

  • 15
  • Issue

  • 6